Compare TANH & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | ACXP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.8M |
| IPO Year | 2015 | 2021 |
| Metric | TANH | ACXP |
|---|---|---|
| Price | $1.00 | $2.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 49.7K | ★ 57.8K |
| Earning Date | 05-15-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.88 | N/A |
| Revenue | ★ $41,982,988.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $2.44 |
| 52 Week High | $6.98 | $21.00 |
| Indicator | TANH | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 35.73 |
| Support Level | $0.98 | $2.65 |
| Resistance Level | $1.05 | $3.07 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 62.46 | 27.27 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments: the Consumer Product segment, and the Electric Vehicle (EV) segment.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.